CLINICAL_TRIALS
trial_result
· 2015-12-18
Clinical Trial Update: Phase II Study of Grass Pollen Allergy Vaccine BM32 [Phase 2]
Summary
Phase II clinical trial evaluating BM32, a grass pollen allergy vaccine developed by Biomay AG, has completed.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: Biomay AG | Conditions: Grass Pollen Allergy | Phase 2 | Status: COMPLETED